Jump to content

Atogepant: Difference between revisions

From Pharmacopedia
[unchecked revision][unchecked revision]
Auto-created stub
 
Expand stub to full MedTemplate parameter set
Line 1: Line 1:
{{MedTemplate
{{MedTemplate
| generic           = Atogepant
| generic           = Atogepant
| brand             = Qulipta
| brand             = Qulipta
| classes           = Gepant, Migraine medicine
| structure          =
| mechanism         = CGRP receptor antagonist
| classes           = Gepant, Migraine medicine
| mechanism         = CGRP receptor antagonist
| uses              =
| starting_dose      =
| preparations      =
| routes            =
| onset              =
| duration          =
| halflife          =
| bioavailability    =
| pregnancy          =
| legal              =
| intro              =
| pharmacokinetics  =
| pharmacodynamics  =
| indications        =
| dosing            =
| effects            =
| contraindications  =
| interactions      =
| pregnancy_details  =
| monitoring        =
| counseling        =
| anecdotes          =
| seealso            =
| references        =
}}
}}
[[Category:Analgesics]]
[[Category:Analgesics]]



Revision as of 01:00, 13 May 2026

Gepant, Migraine medicine
Atogepant
Qulipta

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Common uses
Classification(s)
Classes
Gepant, Migraine medicine
Pharmacology
Purported mechanism
CGRP receptor antagonist
Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the full disclaimer.